IMV Inc.
Index- P/E- EPS (ttm)-0.63 Insider Own0.70% Shs Outstand82.21M Perf Week-8.49%
Market Cap69.83M Forward P/E- EPS next Y-0.45 Insider Trans0.00% Shs Float81.79M Perf Month-25.27%
Income-51.80M PEG- EPS next Q-0.14 Inst Own20.65% Short Float0.98% Perf Quarter-52.11%
Sales0.20M P/S349.14 EPS this Y-14.10% Inst Trans- Short Ratio10.79 Perf Half Y-45.10%
Book/sh0.18 P/B3.75 EPS next Y5.60% ROA- Target Price- Perf Year-68.74%
Cash/sh0.36 P/C1.89 EPS next 5Y- ROE- 52W Range0.56 - 2.41 Perf YTD-44.65%
Dividend- P/FCF- EPS past 5Y-11.90% ROI-86.70% 52W High-71.98% Beta1.98
Dividend %- Quick Ratio3.80 Sales past 5Y-2.10% Gross Margin- 52W Low20.13% ATR0.07
Employees97 Current Ratio3.80 Sales Q/Q- Oper. Margin- RSI (14)36.99 Volatility8.55% 8.97%
OptionableYes Debt/Eq1.70 EPS Q/Q-26.00% Profit Margin- Rel Volume0.68 Prev Close0.65
ShortableYes LT Debt/Eq1.67 EarningsMay 13 BMO Payout- Avg Volume74.12K Price0.68
Recom2.00 SMA20-12.54% SMA50-28.92% SMA200-48.07% Volume50,093 Change3.12%
Sep-22-21Initiated Cantor Fitzgerald Overweight $4
Jul-23-21Resumed Wells Fargo Overweight $14
May-18-20Upgrade Wells Fargo Equal Weight → Overweight
Apr-01-20Downgrade B. Riley FBR Buy → Neutral $7 → $3
Feb-25-20Downgrade Wells Fargo Overweight → Equal Weight
Jan-28-20Initiated BTIG Research Buy $8
Jan-21-20Upgrade Wells Fargo Equal Weight → Overweight
Nov-26-19Initiated Oppenheimer Outperform
Oct-28-19Initiated Wells Fargo Market Perform
May-29-19Initiated B. Riley FBR Buy
Mar-25-19Initiated H.C. Wainwright Buy $11.50
Jun-30-22 07:05AM  
Jun-22-22 07:05AM  
May-17-22 08:05AM  
May-13-22 07:05AM  
May-06-22 07:05AM  
Apr-28-22 07:05AM  
Apr-22-22 07:05AM  
Apr-08-22 05:00PM  
Apr-06-22 07:05AM  
Apr-04-22 07:05AM  
Mar-17-22 07:05AM  
Mar-10-22 07:05AM  
Mar-09-22 07:05AM  
Feb-17-22 07:05AM  
Jan-13-22 09:16AM  
Jan-12-22 07:05AM  
Jan-05-22 07:05AM  
Dec-22-21 07:05AM  
Dec-21-21 07:05AM  
Dec-20-21 07:05AM  
Dec-02-21 07:05AM  
Nov-30-21 07:05AM  
Nov-23-21 08:05AM  
Nov-22-21 08:05AM  
Nov-17-21 11:32AM  
Nov-10-21 05:05PM  
Nov-09-21 08:05AM  
Nov-04-21 07:05AM  
Oct-07-21 09:05AM  
Oct-01-21 08:05AM  
Sep-30-21 04:35PM  
Sep-01-21 07:05AM  
Aug-11-21 10:01PM  
Aug-10-21 07:11AM  
Aug-04-21 08:30AM  
Aug-02-21 07:05AM  
Jul-29-21 07:05AM  
Jul-20-21 10:05AM  
Jul-15-21 09:11AM  
Jul-14-21 04:05PM  
Jun-18-21 04:05PM  
Jun-12-21 03:42AM  
Jun-09-21 07:05AM  
Jun-08-21 07:05AM  
May-13-21 07:05AM  
May-12-21 07:30PM  
May-11-21 07:05AM  
May-10-21 07:05AM  
Apr-29-21 07:05AM  
Apr-13-21 07:05AM  
Apr-09-21 08:30AM  
Apr-08-21 05:30AM  
Apr-07-21 08:54AM  
Mar-25-21 07:05AM  
Mar-17-21 02:30PM  
Mar-10-21 12:30PM  
Mar-08-21 07:05AM  
Mar-01-21 07:05AM  
Jan-04-21 07:05AM  
Dec-28-20 07:38AM  
Dec-10-20 06:00AM  
Dec-09-20 10:40AM  
Dec-06-20 08:15AM  
Dec-03-20 07:10AM  
Nov-13-20 07:05AM  
Nov-12-20 07:05AM  
Nov-10-20 07:05AM  
Nov-09-20 05:05PM  
Nov-04-20 05:05PM  
Oct-29-20 07:05AM  
Oct-16-20 04:48PM  
Oct-15-20 07:05AM  
Oct-08-20 07:05AM  
Sep-16-20 07:05AM  
Sep-04-20 06:01PM  
Sep-02-20 10:22AM  
Aug-26-20 07:05AM  
Aug-12-20 08:25AM  
Aug-11-20 09:28AM  
Aug-05-20 12:30PM  
Aug-03-20 07:05AM  
Jul-29-20 07:05AM  
Jul-23-20 10:20AM  
Jul-20-20 03:35PM  
Jul-17-20 08:51AM  
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.